News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Joshua S. Baker, Ph.D. Named President, CEO Of inGenium Research, Inc.

10/19/2005 5:11:18 PM

CARY, N.C., May. 14 /PRNewswire/ -- Joshua S. Baker, Ph.D., an industry executive with more than 20 years of pharmaceutical management and drug development experience, has been appointed president and chief executive officer of inGenium Research, Inc, a privately held Contract Research Organization headquartered in Cary, North Carolina.

Dr. Baker, 48, most recently served as president and CEO of PPGx, Inc. a pharmacogenomics research and development company.

Before that he was executive vice president of global operations for PPD Development, Inc., a wholly owned subsidiary of PPD, a leading global CRO. Dr. Baker joined PPD Development in 1994 as vice president for biostatistics, data management and information services. A year later, he became senior vice president of operations and was responsible for integration and management of the company's global clinical operations.

During his tenure, PPD Development became one of the top four companies in the global clinical research industry in terms of revenue and size.

"On behalf of the inGenium Research Board of Directors, I am pleased to welcome Dr. Baker as the CEO of inGenium Research," said Jim Baker, chairman of the board for InGenium Research. "His leadership and expertise in global clinical development and his experience with emerging growth companies will prove invaluable to inGenium Research in its quest to become the premier CRO."

Dr. Baker earned his doctorate and master's degrees in statistics from the Texas A&M University and his bachelor's in mathematical science from Penn State University.

inGenium Research is a privately held CRO located in Cary, North Carolina, focused on providing clinical research and strategic development services to pharmaceutical and biotechnology companies. inGenium provides assistance to companies in the areas of strategic planning, technology transfer, licensing, regulatory planning and submissions, pre-clinical development, and manufacturing, as well as providing fully integrated clinical trials support of clinical operations, data management and biostatistics, and regulatory dossier compilations.

For information contact: Josh Baker, President and CEO Dan Headrick inGenium Research, Inc. Public Relations 919.462.8867 919.332.9303

inGenium Research, Inc.

CONTACT: Josh Baker, President and CEO of inGenium Research, Inc.,+1-919-462-8867, or; or Dan Headrick, Public Relationsfor inGenium Research, Inc., +1-919-332-9303, or

Read at

comments powered by Disqus